Michael E. Wechsler, MD, MMSc

Co-Director, The Cohen Family Asthma Institute
Department of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health, Denver, CO


Dr. Wechsler is Co-Director of the National Jewish Cohen Family Asthma Institute and a Professor of Medicine in the Division of Pulmonary, Critical Care & Sleep Medicine of the Department of Medicine at National Jewish Health in Denver.

Prior to his current position as Director of Asthma in the Department of Medicine at National Jewish Health, Dr. Wechsler was on faculty at Harvard Medical School and served as Associate Director of the Brigham & Women’s Hospital Asthma Research Center, where he designed and led clinical trials in asthma and eosinophilic lung diseases. He has expertise in phenotyping asthma subjects and experience in investigating patients with severe asthma.  He has more than 150 peer-reviewed publications, almost all relating to asthma, Churg-Strauss Syndrome, or eosinophilic lung diseases, in journals including the New England Journal of Medicine, the Lancet, and JAMA.  His research interests have been related to clinical and translational asthma & therapeutics, asthma pharmacogenomics, and the treatment and management of Churg-Strauss syndrome (CSS).  He is recognized as an international leader in CSS and eosinophilic lung diseases, treating one of the largest cohorts of patients with this disorder in the US. He has been an investigator in the NHLBI Asthma Clinical Research Network (ACRN) (now known as AsthmaNet), the NHLBI-sponsored Severe Asthma Research Program (SARP), and an NHLBI grant examining imatinib in severe asthma. He has expertise in clinical trial design and management, including serving as PI in a current multi-center NHLBI/ACRN trial examining asthma in Blacks (BARD), serving as PI in an NIH study examining the role of placebo in asthma (Wechsler NEJM 2011), and serving as PI of a large multi-center AHRQ funded study examining treatment of asthma in Blacks (Wechsler JAMA 2015). He has participated in many different task forces related to the study of eosinophilic lung diseases (including CSS) that have been sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society.

Clinically, Dr. Wechsler has an active outpatient practice at National Jewish Health in which he primarily sees patients with Churg-Strauss syndrome, eosinophilic pneumonia and severe refractory asthma. He also practices critical care medicine in the Intensive care unit of Denver’s Rose Hospital and Swedish Medical Center where he enjoys teaching medical students, residents, and fellows. Dr. Wechsler also serves as Associate Editor of the Journal Allergy and is on the editorial Board of the European Journal of Clinical Investigation.

Dr. Wechsler received his undergraduate degree in Biochemical Sciences from Harvard College, his medical education from McGill University in Montreal, a Masters in Medical Science from Harvard Medical School, and completed postgraduate internal medicine training at Harvard’s Beth Israel Hospital in Boston and his pulmonary training at the Harvard Combined Fellowship in Pulmonary & Critical Care Medicine. He is board certified in Pulmonary & Critical Care Medicine.

National Jewish Health
1400 Jackson Street
Denver, CO 80206
© 2017 National Jewish Health

Grant Statement
This educational activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, and Sanofi Genzyme and Regeneron Pharmaceuticals.